Our company aims to create a healthier future for patients while increasing shareholder value through the development and introduction of quality, affordable generic products by experienced, passionate and talented pharmaceutical professionals.
Praxgen is a specialty pharmaceutical company focused on development, manufacturing and marketing of high-quality generic prescription pharmaceuticals that improve patient health while creating stakeholder value. We specialize in difficult-to-manufacture and complex dosage forms, including ophthalmics, injectables, topicals and oral solids.
We have Research and Development facilities in Princeton, NJ and Monmouth Junction, NJ, and several manufacturing facilities across North America and Asia through partnerships and contract manufacturing.
Praxgen has over 40 products under development at various stages that have been and will be filed with the FDA and Chinese FDA.
Praxgen Pharmaceuticals, formerly SunGen Pharma, was founded in 2016 by a team of distinguished pharma executives. The name Praxgen reflects our commitment to a practical and accessible path to patient health through high-quality generic pharmaceuticals.
We are excited to announce that SunGen Pharma has rebranded as Praxgen Pharmaceuticals!
Over the past five years, SunGen focused on actively building a company that can both develop a wide range of drug products while maintaining flexibility and dedication to R&D fundamentals. SunGen is not and has never been affiliated with SUN PHARMA® and/or Sun Pharmaceutical Industries, Ltd.
Our new name, Praxgen Pharmaceuticals, reflects our commitment to patient health. The path to health should be practical and accessible to everyone, and we aim to help achieve that through high-quality generic pharmaceuticals.
Amidst this thrilling name change, Praxgen’s quality remains constant. We will continue to focus on developing exemplary prescription drugs for introduction into the market to bring accessibility to the masses.
Oakrum and SunGen announced the U.S. launch and commercial shipment of a generic version of Medrol® (Methylprednisolone) in 4 mg tablets. It is anticipated that the product will serve the retail market with annual sales in the U.S. exceeding $110 million in the aggregate for the 12-month period ending December 31, 2018 according to available data from IQVIA.
The seventh approved ANDA is for Fosaprepitant for Injection 150mg/vial. This drug product is used for treatment of cyclic vomiting syndrome and late-stage, chemotherapy-induced vomiting. This is a sub-blockbuster product of over $350M US market size for 2018 according to IQVIA. Emend®’s patent expired on Sep 4th and SunGen obtained its ANDA approval on Sep 5th, which includes it in the first wave of all generic approvals for Emend®.
Please reach out to us with any business inquiries.
9 Deerpark Dr, Suite J-10, Monmouth Junction, New Jersey 08852, United States
Monday - Friday: 9am - 5pm
Saturday - Sunday: Closed
Copyright © 2024 Praxgen PHARMACEUTICALS - All Rights Reserved.